Never ignore a small cap stock just because it appears to be down-and-out.

You may just miss a triple-digit profit opportunity.

Look at Axsome Therapeutics (AXSM), for example.

Since the start of the year, the stock has exploded from $2 to $14.30.

Axsome Therapeutics is a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The Company’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimer’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes.

While that may sound like a snore-fest stock, that couldn’t be further from the truth.

The stock is now the biggest stock winners of the year so far as a result.

All thanks to positive clinical data regarding one of its depression drugs, AXS-05 – which significantly improved depression symptoms after six months when compared with bupropion. The drug was also deemed to be safe and well-tolerated with no serious side effects.

“The clinically meaningful improvements in depressive symptoms seen with AXS-05 in this study were achieved versus an active comparator that is a well-established antidepressant, as early as only one week after initiation of treatment,” said Professor Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry, Massachusetts General Hospital (MGH) and Associate Dean for Clinical & Translational Research, Harvard Medical School.

However, AXSM isn’t the only biotech stock we believe could rocket higher.

Here are two others that may have similar, explosive upside.

Biotech Stock No. 1 -- Nabriva Therapeutics 

At the moment, the stock is consolidating with heavy volume.  As we near June 30, 2019, we believe the stock could push significantly higher. That’s when the FDA will rule on its Contepo IV drug for the treatment of complicated urinary tract infections.  If approved, it will be a first-in-class intravenous (IV) antibiotic with broad spectrum activity against Gram-negative and Gram-positive organisms, including ESBL-producing Enterobacteriaceae and other multi-drug resistant organisms. Annually, some three million cases of cUTIs require hospital treatment in the U.S. for Gram-negative infections.

Biotech Stock No. 2 -- Heron Therapeutics 

The stock is just beginning to accelerate higher, as we near the FDA’s April 30, 2019 decision on HTX-011 for the management of post-operative pain.  In studies, patients injected with HTX-011 reported significantly less pain intensity than those given bupivacaine.  It also has proof that shows that patients given HTX-011 were less likely to require opioid rescue medications.